 | February 1, 2010
By:William Looney
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
 |
 | February 1, 2010
By:Walter Armstrong
The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?
|
 | January 27, 2010
By:William Looney
In a disruptive era of change, old-fashioned intuition still counts.
|
 | January 22, 2010
GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged.
|
 | January 20, 2010
By:Walter Armstrong
Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?
|
 | January 13, 2010
By:George Koroneos
A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more.
|
 | January 6, 2010
By:Jill Wechsler
FDA Commissioner Margaret Hamburg has a history of health advocacy and a clear mandate to transform the agency. But can she succeed where others have failed?
|
 | December 9, 2009
By:Brittany Agro
This year's winning brand advertising campaigns convey compelling messages with eye-catching graphics and creative copy.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?